159 related articles for article (PubMed ID: 22948119)
1. Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Dellanna F; Reichel H; Seibt F
Clin Nephrol; 2012 Nov; 78(5):382-90. PubMed ID: 22948119
[TBL] [Abstract][Full Text] [Related]
2. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Keith MS; Wilson RJ; Preston P; Copley JB
Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
[TBL] [Abstract][Full Text] [Related]
4. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Hutchison AJ; Laville M;
Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
[TBL] [Abstract][Full Text] [Related]
5. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Wilson RJ; Keith MS; Preston P; Copley JB
Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
[TBL] [Abstract][Full Text] [Related]
6. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
8. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskuhler A
Nephron Clin Pract; 2005; 100(1):c8-19. PubMed ID: 15809508
[TBL] [Abstract][Full Text] [Related]
10. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
[TBL] [Abstract][Full Text] [Related]
12. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
[TBL] [Abstract][Full Text] [Related]
13. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
14. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
15. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
[TBL] [Abstract][Full Text] [Related]
16. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Huang W; Liu J; Tang Y; Gao X; Di B; Zhang F
Curr Med Res Opin; 2014 Jan; 30(1):99-108. PubMed ID: 24063635
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
20. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Vemuri N; Michelis MF; Matalon A
BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
